Pharmaceutical

NMPA approves Astellas’ PADCEV for advanced urothelial cancer

China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved Astellas’ PADCEV (enfortumab vedotin).

Aug 21, 2024 - 04:00
NMPA approves Astellas’ PADCEV for advanced urothelial cancer
China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved Astellas’ PADCEV (enfortumab vedotin).
Read the original article

Tags:

Previous Article

Colombia’s president signs law to strengthen pharmaceutical sector

Next Article

Homemade Hair Growth Shampoo

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases

Sandoz’s Afqlir gains EC marketing authorisation for re...

Nov 19, 2024

Long Covid research funding at NIH gets a nearly 50% boost

Long Covid research funding at NIH gets a nearly 50% boost

Feb 15, 2024

Ikena further sheds staff and pipeline in bid to maximise value

Ikena further sheds staff and pipeline in bid to maximi...

May 31, 2024